Table 1.

Infections with thrombotic and throemboembolic complications and possible similarities to those of infection SARS-CoV-2

Infectious agent	Thrombotic or thromboembolic complications	Therapeutic possibilities
HIV infection	VTE Pulmonary hypertension Endothelial dysfunction Inflammation	Anticoagulants Pulm. vasodilatator Anti-inflammatory drugs
HCV infection	VTE Pulmonary hypertension	Anticoagulants Pulm. vasodilatator
Respiratory infections	Myocardial Infarction Ischemic stroke Venous thrombosis	Anticoagulants Thrombolysis Antiaggregants
Pneumococcal pneumonia	Major adverse cardiac events (total death, Myocardial infarction, ischemic stroke, HF hospitalization)	Antiaggregants
S. pneumoniae or flu pneumonia	VTE Atherosclerotic events	Anticoagulants Antiaggregants
Chlamydia pneumoniae	Coronary artery disease	Antibiotic therapy
Helicobacter pylori	Coronary artery disease	Antibiotic therapy
Mycoplasma pneumoniae	Coronary artery disease	Antibiotic therapy

HIV human immunodeficiency virus, VTE venous thromboembolism, HCV hepatitis C virus, HF heart failure, Pulm pulmonary, S streptococcus